AFMD has been the subject of several other research reports. Wells Fargo & Company reaffirmed an overweight rating on shares of Affimed in a report on Thursday, August 18th. Stifel Nicolaus downgraded Affimed from a buy rating to a hold rating and dropped their target price for the stock from $9.00 to $2.00 in a report on Monday, October 10th. Finally, Cantor Fitzgerald reissued an overweight rating on shares of Affimed in a report on Wednesday, September 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $7.50.
Affimed Trading Up 6.4 %
Shares of Affimed stock opened at $2.16 on Monday. The business has a fifty day simple moving average of $1.96 and a two-hundred day simple moving average of $2.59. Affimed has a 1 year low of $1.40 and a 1 year high of $7.35. The company has a market capitalization of $266.59 million, a price-to-earnings ratio of -3.43 and a beta of 2.19. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.65 and a quick ratio of 5.63.
Institutional Inflows and Outflows
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.
- Get a free copy of the StockNews.com research report on Affimed (AFMD)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.